Hydroxychloroquine-induced hyperpigmentation of the skin and bull’s-eye maculopathy in rheumatic patients: a case report and literature review

Ji-peng Peng, Xiaoyu Yang, Feng Luo, Xuemei Yuan, Hong Xiong, Wukai Ma, Xueming YaoFrontiers in Immunology 2024 · DOI

This paper, published in Frontiers in Immunology, provides a detailed clinical account and literature synthesis regarding the dual toxicity of Hydroxychloroquine (HCQ)—a mainstay treatment for autoimmune diseases—on both the skin and the retina.

TL;DR

The study documents a rare case of a patient developing concurrent skin hyperpigmentation and irreversible "bull’s-eye" maculopathy after three years of hydroxychloroquine therapy. While the skin discoloration partially resolved upon drug discontinuation, the retinal damage persisted, highlighting the urgent need for clinicians to monitor cutaneous changes as potential early warning signs of systemic toxicity.

What Problem Does This Paper Address?

Hydroxychloroquine (HCQ) is a widely used disease-modifying antirheumatic drug (DMARD) for conditions like rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). While generally considered safer than its predecessor, chloroquine, HCQ is known to accumulate in pigmented tissues.

The authors address a critical clinical challenge: the recognition of HCQ-induced toxicity that manifests simultaneously in the skin and the eyes. Because ocular damage (maculopathy) is often irreversible and can lead to blindness, identifying early markers—such as specific skin changes—is vital for preventing permanent disability.

Methods

The authors employed a multimodal diagnostic approach to evaluate a 65-year-old female patient:

  • Ophthalmological Imaging: Used Optical Coherence Tomography (OCT) to visualize retinal layers and fundus screening to identify the characteristic "bull’s-eye" lesion.
  • Dermatopathological Analysis: Performed a skin biopsy using multiple staining techniques, including Hematoxylin and Eosin (HE) and Fontana-Masson (which identifies melanin). They also used Prussian blue and silver hexamine stains to rule out other types of pigment deposition.
  • Literature Review: Conducted a systematic search across PubMed, Embase, and Web of Science for cases published up to December 2023, filtering for HCQ-induced hyperpigmentation and maculopathy.

Datasets

As a case report and review, the "dataset" consists of the clinical findings from the primary patient and a meta-analysis of existing literature:

  • Skin Toxicity Cohort: 18 articles describing 20 cases of HCQ-induced hyperpigmentation.
  • Ocular Toxicity Cohort: 11 articles describing 13 cases of bull’s-eye maculopathy.
  • Primary Case Data: 3 years of clinical history, including a daily HCQ dosage of 400mg and a cumulative dose of approximately 438g.

Key Insights and Ideas

  • The "Warning Sign" Hypothesis: The paper suggests that cutaneous hyperpigmentation may serve as a visible clinical marker for HCQ toxicity. Since HCQ has a high affinity for melanin, it accumulates in both the skin and the retinal pigment epithelium (RPE).
  • Reversibility Mismatch: A key "aha moment" is the difference in recovery: skin pigmentation often fades after stopping the drug (as seen in this patient after 3 months), but the "bull’s-eye" retinal damage is typically permanent because the photoreceptors and RPE cells do not regenerate.
  • Anatomical Specificity: HCQ-induced skin changes often present as blue-gray or dark brown patches, specifically on the face, neck, and limbs. In the eye, the damage is localized to the macula, creating a ring-like appearance of atrophy.
  • Alternative Therapies: The authors highlight the use of iguratimod (primarily used in China and Japan) as an effective alternative DMARD for RA patients who must discontinue HCQ due to toxicity.

Key Results

  • Clinical Outcome: After stopping HCQ, the patient’s skin hyperpigmentation "gradually reduced," but her blurred vision showed "no significant improvement."
  • Literature Trends: The review found that most skin hyperpigmentation cases occurred at a daily dose of 400mg, with onset ranging from 3 months to 22 years.
  • Ocular Thresholds: Retinal toxicity was most common in patients with cumulative doses exceeding 400g or those who had used the drug for over five years, though the primary case showed damage at just 3 years.
  • Biopsy Findings: Fontana-Masson staining confirmed a significant increase in melanin in the basal layer of the epidermis, while Prussian blue was negative, ruling out iron-based discoloration (hemosiderin).

Limitations and Future Work

The authors acknowledge that while a link between skin and eye toxicity is observed, the exact biochemical mechanism remains partially unknown. The study is limited by its nature as a single case report, which cannot establish a definitive statistical correlation between the severity of skin changes and the degree of retinal damage.

Future research is needed to determine if specific dermatological patterns can quantitatively predict the risk of maculopathy. The authors conclude by urging a multidisciplinary approach: rheumatologists should perform regular skin checks, and any new pigmentation should trigger an immediate, high-resolution ophthalmological referral.

Summary updated

Abstract

Hydroxychloroquine (HCQ) is used as a traditional disease-modifying antirheumatic drugs (DMARDs), for the treatment of autoimmune diseases such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). However, it can cause serious adverse reactions, including hyperpigmentation of the skin and bull's-eye macular lesions. Here, we present a case of HCQ-induced hyperpigmentation of the skin and bull's-eye macular lesions in a patient who received HCQ for RA. A 65-year-old female patient developed blurred vision and hyperpigmentation of multiple areas of skin over the body for one month after 3 years of HCQ treatment for RA. Based on clinical presentation, ophthalmological examination and dermatopathological biopsy, a diagnosis of drug-induced cutaneous hyperpigmentation and bullous maculopathy of the right eye was made. After discontinuation of HCQ and treatment with iguratimod tablets, the hyperpigmentation of the patient 's skin was gradually reduced, and the symptoms of blurred vision were not significantly improved. We also reviewed the available literature on HCQ-induced cutaneous hyperpigmentation and bull's-eye macular lesions and described the clinical features of HCQ-induced cutaneous hyperpigmentation and bull's-eye macular lesions. In conclusion, clinicians should be aware of early cutaneous symptoms and HCQ-associated ophthalmotoxicity in patients with rheumatic diseases on HCQ sulphate and should actively monitor patients, have them undergo regular ophthalmological examinations and give appropriate treatment to prevent exacerbation of symptoms.
BibTeX
@inproceedings{peng2024hydroxychloroquine,
  author = {Ji-peng Peng and Xiaoyu Yang and Feng Luo and Xuemei Yuan and Hong Xiong and Wukai Ma and Xueming Yao},
  title = {{Hydroxychloroquine-induced hyperpigmentation of the skin and bull’s-eye maculopathy in rheumatic patients: a case report and literature review}},
  booktitle = {Frontiers in Immunology},
  year = {2024},
  doi = {10.3389/fimmu.2024.1383343},
}
Figure